Norgine Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment

Key Takeaways

• European Commission grants marketing authorization for XOLREMDI (mavorixafor) as the first treatment for WHIM syndrome in the EU
• Approval addresses critical unmet medical need for patients with this ultra-rare primary immunodeficiency disorder
• Authorization granted under exceptional circumstances following positive recommendation from EMA’s CHMP committee

---

AMSTERDAM, April 29, 2026 — Norgine, a leading European specialty pharmaceutical company, announced today that the European Commission has granted marketing authorization for XOLREMDI® (mavorixafor), making it the first authorized treatment for patients with WHIM syndrome in the European Union.

Breakthrough for Ultra-Rare Disease

The approval represents a significant milestone for patients living with WHIM syndrome, an ultra-rare primary immunodeficiency disorder that affects the immune system’s ability to fight infections. The European Commission granted the authorization under exceptional circumstances, a regulatory pathway reserved for treatments addressing serious conditions with limited treatment options.

The decision follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), which recommended approval based on available clinical evidence demonstrating the drug’s potential benefits for this patient population.

Understanding WHIM Syndrome

WHIM syndrome is an extremely rare genetic disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis. Patients with this condition experience recurrent infections due to compromised immune function, significantly impacting their quality of life and long-term health outcomes.

Mavorixafor works as a CXCR4 antagonist, targeting specific cellular pathways involved in immune cell function. This mechanism of action addresses the underlying pathophysiology of WHIM syndrome, offering patients their first targeted therapeutic option.

Market Impact and Commercial Implications

As the first authorized treatment for WHIM syndrome in Europe, XOLREMDI enters an exclusive market with no direct competition. The orphan drug designation provides Norgine with market exclusivity and potential pricing advantages, though the commercial opportunity remains limited due to the ultra-rare nature of the condition.

The exceptional circumstances approval pathway indicates that while clinical data may be limited compared to standard approvals, the regulatory authorities determined that the benefits outweigh the risks for this patient population with no alternative treatment options.

Regulatory Precedent and Future Outlook

This European approval establishes an important regulatory precedent that could facilitate approvals in other markets worldwide. The successful navigation of the exceptional circumstances pathway demonstrates the viability of this regulatory approach for ultra-rare diseases with significant unmet medical needs.

For Norgine, the approval strengthens its position in the rare disease space and validates its specialty pharmaceutical strategy. The company’s focus on addressing unmet medical needs in underserved patient populations aligns with growing industry trends toward orphan drug development.

Patient Access and Availability

With marketing authorization secured, Norgine will now work with individual EU member states to establish pricing and reimbursement agreements. The timeline for patient access will vary by country, depending on local health technology assessment processes and healthcare system requirements.

The company has indicated its commitment to ensuring appropriate patient access while working with healthcare providers to establish treatment protocols and monitoring guidelines for this new therapeutic option.

---

Frequently Asked Questions

What is WHIM syndrome and how many patients does it affect?

WHIM syndrome is an ultra-rare genetic primary immunodeficiency disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis. It affects a very small number of patients worldwide, making it one of the rarest immunodeficiency conditions.

When will XOLREMDI be available to patients in Europe?

While the European Commission has granted marketing authorization, availability will depend on individual EU member state pricing and reimbursement negotiations. Patients should consult with their healthcare providers about access timelines in their specific countries.

How does XOLREMDI compare to existing WHIM syndrome treatments?

XOLREMDI is the first authorized treatment specifically for WHIM syndrome in the European Union. Previously, patients had no targeted therapeutic options and relied on supportive care measures to manage symptoms and infections.